CN113004205B - Ppar激动剂、化合物、药物组合物及其使用方法 - Google Patents

Ppar激动剂、化合物、药物组合物及其使用方法 Download PDF

Info

Publication number
CN113004205B
CN113004205B CN202110284826.5A CN202110284826A CN113004205B CN 113004205 B CN113004205 B CN 113004205B CN 202110284826 A CN202110284826 A CN 202110284826A CN 113004205 B CN113004205 B CN 113004205B
Authority
CN
China
Prior art keywords
methyl
mmol
compound
imidazol
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110284826.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113004205A (zh
Inventor
M·唐斯
R·M·埃文斯
A·克鲁格
B·拉古
三浦理宪
S·K·潘尼格拉西
M·帕塔内
S·萨玛杰达尔
R·瑟耐尔
高桥泰辅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellai Engineering Small Molecule Usa Co ltd
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57200096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113004205(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Institute for Biological Studies, Mitobridge Inc filed Critical Salk Institute for Biological Studies
Priority to CN202110284826.5A priority Critical patent/CN113004205B/zh
Publication of CN113004205A publication Critical patent/CN113004205A/zh
Application granted granted Critical
Publication of CN113004205B publication Critical patent/CN113004205B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202110284826.5A 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法 Active CN113004205B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110284826.5A CN113004205B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562238629P 2015-10-07 2015-10-07
US62/238,629 2015-10-07
US201562243263P 2015-10-19 2015-10-19
US62/243,263 2015-10-19
US201662352348P 2016-06-20 2016-06-20
US62/352,348 2016-06-20
CN201680057879.0A CN108349904B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法
PCT/US2016/055521 WO2017062468A1 (en) 2015-10-07 2016-10-05 Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN202110284826.5A CN113004205B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680057879.0A Division CN108349904B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法

Publications (2)

Publication Number Publication Date
CN113004205A CN113004205A (zh) 2021-06-22
CN113004205B true CN113004205B (zh) 2024-07-02

Family

ID=57200096

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110284826.5A Active CN113004205B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法
CN202110286947.3A Active CN113024467B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法
CN201680057879.0A Active CN108349904B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110286947.3A Active CN113024467B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法
CN201680057879.0A Active CN108349904B (zh) 2015-10-07 2016-10-05 Ppar激动剂、化合物、药物组合物及其使用方法

Country Status (26)

Country Link
US (6) US10399958B2 (enExample)
EP (3) EP3359528B1 (enExample)
JP (2) JP6657413B2 (enExample)
KR (2) KR102667385B1 (enExample)
CN (3) CN113004205B (enExample)
AU (3) AU2016333963C1 (enExample)
BR (1) BR112018006866B1 (enExample)
CA (1) CA3000431A1 (enExample)
CO (1) CO2018004473A2 (enExample)
DK (1) DK3359528T3 (enExample)
EA (1) EA037371B1 (enExample)
ES (3) ES2906379T3 (enExample)
HU (1) HUE058154T2 (enExample)
IL (3) IL258225B (enExample)
JO (3) JO3738B1 (enExample)
MA (2) MA52098A (enExample)
MX (3) MX380281B (enExample)
MY (1) MY203081A (enExample)
PH (1) PH12018500762A1 (enExample)
PL (1) PL3359528T3 (enExample)
PT (1) PT3359528T (enExample)
SG (1) SG10201906400SA (enExample)
TW (3) TWI730006B (enExample)
UA (1) UA122237C2 (enExample)
WO (1) WO2017062468A1 (enExample)
ZA (4) ZA201802029B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122237C2 (uk) * 2015-10-07 2020-10-12 Мітобрідж, Інк. Агоністи ppar, сполуки, фармацевтичні композиції та способи їх застосування
MX380531B (es) 2016-04-13 2025-03-12 Mitobridge Inc Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos.
WO2018067857A1 (en) * 2016-10-05 2018-04-12 Mitobridge, Inc. Methods of treating acute kidney injury
ES2887008T3 (es) * 2016-10-05 2021-12-21 Mitobridge Inc Formas cristalinas y de sal de compuestos agonistas del PPAR
WO2021046081A1 (en) * 2019-09-05 2021-03-11 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
EP4305024A1 (en) * 2021-03-08 2024-01-17 Abionyx Pharma SA Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
US20240358681A1 (en) 2021-06-02 2024-10-31 Mitobridge, Inc. Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
WO2025207099A1 (en) 2024-03-28 2025-10-02 Astellas Pharma Inc. Ppar-delta inhibitors for preventing post-operative atrial fibrillation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349904B (zh) * 2015-10-07 2021-08-31 米托布里奇公司 Ppar激动剂、化合物、药物组合物及其使用方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228281A (en) 1977-09-23 1980-10-14 Ciba-Geigy Corporation Dicarboxylic acids containing triazine rings
DE4123341A1 (de) 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
EP1159263A1 (en) 1999-02-26 2001-12-05 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
WO2002014285A1 (en) 2000-08-17 2002-02-21 Pfizer Limited Substituted imidazoles as tafia inhibitors
RU2328483C2 (ru) * 2002-08-29 2008-07-10 Мерк Энд Ко., Инк. Индолы, обладающие противодиабетической активностью
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
WO2004060367A1 (en) 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
WO2005030185A2 (en) 2003-09-26 2005-04-07 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
CN101031541A (zh) 2004-09-06 2007-09-05 弗·哈夫曼-拉罗切有限公司 4－氨基甲基苄脒衍生物及其作为因子Ⅷa抑制剂的用途
CN101119974A (zh) 2005-02-15 2008-02-06 霍夫曼-拉罗奇有限公司 作为ppar活化剂的酰胺衍生物
KR20080042170A (ko) * 2005-09-07 2008-05-14 플렉시콘, 인코퍼레이티드 Ｐｐａｒ 활성 화합물
BRPI0707338A2 (pt) 2006-01-30 2011-05-03 Transtech Pharma Inc derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase
WO2007110237A2 (en) 2006-03-28 2007-10-04 Novartis Ag Amide derivatives and their application for the treatment of g protein related diseases
NZ572268A (en) 2006-04-18 2011-09-30 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta (ppar)
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
CN101085772A (zh) 2006-06-07 2007-12-12 上海艾力斯医药科技有限公司 一类具有PPARγ激动剂活性的化合物及其应用
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
KR20080082541A (ko) 2007-03-07 2008-09-11 동아제약주식회사 퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도
JP2008285452A (ja) 2007-05-21 2008-11-27 Ono Pharmaceut Co Ltd ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
EP2234622A4 (en) 2007-12-28 2011-03-09 Salk Inst For Biological Studi METHODS ENHANCING PERFORMANCE AND MUSCLE TONUS
ES2607482T3 (es) 2012-08-28 2017-03-31 Koc Universitesi Placa ósea
EP2981522A4 (en) 2013-04-05 2016-08-31 Salk Inst For Biological Studi PPAR AGONISTS
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
WO2016057322A1 (en) * 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
WO2016057658A1 (en) 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX380531B (es) 2016-04-13 2025-03-12 Mitobridge Inc Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos.
ES2887008T3 (es) * 2016-10-05 2021-12-21 Mitobridge Inc Formas cristalinas y de sal de compuestos agonistas del PPAR
WO2018067857A1 (en) 2016-10-05 2018-04-12 Mitobridge, Inc. Methods of treating acute kidney injury
WO2018125961A1 (en) * 2016-12-30 2018-07-05 Mitobridge, Inc. Poly-adp ribose polymerase (parp) inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349904B (zh) * 2015-10-07 2021-08-31 米托布里奇公司 Ppar激动剂、化合物、药物组合物及其使用方法

Also Published As

Publication number Publication date
MA52648A (fr) 2021-10-13
JP2020075939A (ja) 2020-05-21
CO2018004473A2 (es) 2018-09-20
JOP20200230A1 (ar) 2022-10-30
IL275387A (en) 2020-07-30
JO3738B1 (ar) 2021-01-31
ES2988059T3 (es) 2024-11-19
BR112018006866B1 (pt) 2023-11-21
MA52098A (fr) 2021-01-27
IL275392B (en) 2022-05-01
TWI730408B (zh) 2021-06-11
WO2017062468A1 (en) 2017-04-13
JP2018534355A (ja) 2018-11-22
CN108349904A (zh) 2018-07-31
JP6866514B2 (ja) 2021-04-28
MY203081A (en) 2024-06-07
NZ740846A (en) 2024-12-20
IL258225A (en) 2018-05-31
SG10201906400SA (en) 2019-08-27
MX392524B (es) 2025-03-24
EP3770146A1 (en) 2021-01-27
KR20210126150A (ko) 2021-10-19
DK3359528T3 (en) 2022-03-07
JOP20200230B1 (ar) 2024-04-18
US20200157074A1 (en) 2020-05-21
US20190084958A1 (en) 2019-03-21
TW202012375A (zh) 2020-04-01
ZA202003664B (en) 2022-08-31
KR102667386B1 (ko) 2024-05-21
MX2020011099A (es) 2022-05-23
US11578052B2 (en) 2023-02-14
EA037371B1 (ru) 2021-03-19
ES2906379T3 (es) 2022-04-18
AU2019283837A1 (en) 2020-01-16
US20240417383A1 (en) 2024-12-19
MX2018004295A (es) 2018-08-09
MX392523B (es) 2025-03-24
AU2019283837B2 (en) 2020-12-24
UA122237C2 (uk) 2020-10-12
EA201890776A1 (ru) 2018-09-28
US10399958B2 (en) 2019-09-03
IL275387B (en) 2021-08-31
TWI730006B (zh) 2021-06-11
CN108349904B (zh) 2021-08-31
CN113024467A (zh) 2021-06-25
US10479775B1 (en) 2019-11-19
US10906885B2 (en) 2021-02-02
ES2949852T3 (es) 2023-10-03
AU2016333963B2 (en) 2021-01-07
EP3795566A1 (en) 2021-03-24
CN113024467B (zh) 2024-08-06
ZA202003662B (en) 2022-08-31
AU2020281069B2 (en) 2022-10-27
IL258225B (en) 2021-08-31
AU2016333963A1 (en) 2018-04-12
AU2016333963C1 (en) 2021-05-27
CN113004205A (zh) 2021-06-22
US20210253549A1 (en) 2021-08-19
JP6657413B2 (ja) 2020-03-04
CA3000431A1 (en) 2017-04-13
TW201943705A (zh) 2019-11-16
AU2020281069A1 (en) 2021-01-07
EP3359528B1 (en) 2022-01-12
EP3795566B1 (en) 2023-04-19
JOP20200231A1 (ar) 2022-10-30
MX380281B (es) 2025-03-12
KR102667385B1 (ko) 2024-05-21
HK1257907A1 (zh) 2019-11-01
IL275392A (en) 2020-07-30
JOP20200231B1 (ar) 2022-03-14
EP3359528A1 (en) 2018-08-15
EP3770146B1 (en) 2024-07-24
PT3359528T (pt) 2022-04-07
TWI742479B (zh) 2021-10-11
KR20180095797A (ko) 2018-08-28
PH12018500762A1 (en) 2018-10-29
HUE058154T2 (hu) 2022-07-28
US20190337920A1 (en) 2019-11-07
ZA202003663B (en) 2022-08-31
WO2017062468A8 (en) 2017-05-11
EP3770146C0 (en) 2024-07-24
US20230373948A1 (en) 2023-11-23
PL3359528T3 (pl) 2022-05-30
TW201722919A (zh) 2017-07-01
ZA201802029B (en) 2022-01-26
BR112018006866A2 (pt) 2018-10-16
MX2020011100A (es) 2022-05-23

Similar Documents

Publication Publication Date Title
CN113004205B (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK40054571A (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK40054571B (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK40054101A (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK40054101B (zh) Ppar激动剂、化合物、药物组合物及其使用方法
HK1257907B (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40054571

Country of ref document: HK

GR01 Patent grant
CP03 Change of name, title or address

Address after: Massachusetts, USA

Patentee after: Astellai Engineering Small Molecule USA Co.,Ltd.

Country or region after: U.S.A.

Patentee after: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

Address before: Massachusetts, USA

Patentee before: MITOBRIDGE, Inc.

Country or region before: U.S.A.

Patentee before: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

CP03 Change of name, title or address
TR01 Transfer of patent right

Effective date of registration: 20241231

Address after: California, USA

Patentee after: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

Country or region after: U.S.A.

Address before: Massachusetts, USA

Patentee before: Astellai Engineering Small Molecule USA Co.,Ltd.

Country or region before: U.S.A.

Patentee before: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

TR01 Transfer of patent right